Illumina: Scott Gottlieb, Keith Meister, Stephen MacMillan, Carissa Rollins

Illumina has elected Scott Gottlieb as its non-executive chair of the company's board. Gottlieb, who was the commissioner of the US Food and Drug Administration from 2017 to 2019, has served on Illumina's board of directors since 2020. He is currently a partner at the venture capital firm New Enterprise Associates and a senior fellow at the American Enterprise Institute for Public Policy Research. He also serves as a director of the publicly traded companies Pfizer and TempusAI and is a member of the executive committee of the board of the Mount Sinai Medical System.

Illumina has also appointed Keith Meister, founder, managing partner, and chief investment officer of Corvex Management, to its board of directors effective of March 28, 2025. 

Stephen MacMillan, chairman, president, and CEO of Hologic, who joined Illumina's board in June 2023, will retire in preparation for the company's upcoming annual meeting of shareholders. Illumina said MacMillan's resignation "is not the result of any dispute or disagreement with the company or the company's board of directors."

Additionally, Carissa Rollins, Illumina's chief information officer, notified Illumina that she will be retiring effective as of April 11, 2025.